Relapsed / Refractory · Phase III multinational open-label randomized; N=509; SCLC progressing during/after platinum. Tarlatamab vs investigator-choice topotecan/lurbinectedin/amrubicin. Primary endpoint OS. · Median OS 13.6 vs 8.3 months

DeLLphi-304

Clinical question: Does tarlatamab improve OS over chemotherapy after platinum-treated small-cell lung cancer?

Median OS 13.6 vs 8.3 months; HR 0.60 (95% CI 0.47–0.77; P<0.001). PFS and cancer-related dyspnoea/cough also favoured tarlatamab. · Registry:

Design, population and treatment

Phase III multinational open-label randomized; N=509; SCLC progressing during/after platinum. Tarlatamab vs investigator-choice topotecan/lurbinectedin/amrubicin. Primary endpoint OS.

Key efficacy outcome

13.6 · intervention

8.3

13.6 · comparator

Not calculable from median OS; grade ≥3 toxicity favoured tarlatamab.

Grade ≥3 AEs 54% vs 80%; discontinuation due to AEs 5% vs 12%.

Safety and absolute effect

Median OS (months)

https://www.nejm.org/doi/abs/10.1056/NEJMoa2502099

Interpretation and limitations

Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.

Primary source

Primary publication · DOI: 10.1056/NEJMoa2502099